STOCK TITAN

Angiodynamics - ANGO STOCK NEWS

Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.

Overview of AngioDynamics

Founded in 1988 and headquartered in Queensbury, New York, AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices designed to enhance patient care through minimally invasive treatments. The company serves healthcare professionals, including interventional radiologists, nephrologists, and surgeons, by offering advanced solutions for treating cancer, peripheral vascular diseases, and other critical health conditions. AngioDynamics operates within the high-growth medical technology sector, focusing on improving patient outcomes and addressing complex medical challenges.

Core Business and Product Portfolio

AngioDynamics designs, manufactures, and markets a diverse range of medical devices across several key categories:

  • Oncology Solutions: Technologies such as the NanoKnife® System and radiofrequency ablation devices enable precise, minimally invasive treatment of tumors, offering patients less invasive alternatives to traditional surgical procedures.
  • Vascular Access and Peripheral Vascular Devices: Products include angiographic accessories, angioplasty devices, thrombolytic products, and venous solutions, which are critical for managing vascular health and ensuring effective blood flow.
  • Dialysis and Drainage Products: These devices support nephrologists and other healthcare providers in managing kidney-related conditions and fluid drainage requirements.

The company’s commitment to innovation is evident in its focus on developing next-generation technologies that meet the evolving needs of healthcare providers and patients. By prioritizing research and development, AngioDynamics has built a robust portfolio that addresses both diagnostic and therapeutic applications.

Market Position and Competitive Landscape

AngioDynamics operates in a competitive and technologically advanced industry alongside major players such as Medtronic, Boston Scientific, and Abbott. The company differentiates itself through its focus on niche technologies like the NanoKnife® System, which offers a unique approach to cancer treatment by utilizing irreversible electroporation. Additionally, its emphasis on minimally invasive solutions aligns with the broader healthcare trend toward reducing recovery times and improving patient experiences.

While AngioDynamics derives a significant portion of its revenue from the U.S. market, it also seeks to expand its global footprint. Challenges include navigating regulatory environments, maintaining a steady innovation pipeline, and addressing pricing pressures in the healthcare sector.

Commitment to Patient Outcomes and Innovation

AngioDynamics is dedicated to advancing medical care by delivering technologies that improve clinical outcomes. Its minimally invasive devices not only enhance procedural efficiency but also reduce patient recovery times, making them an essential part of modern healthcare practices. The company’s forward-looking strategy involves continuous innovation to address unmet medical needs and adapt to changing industry dynamics.

Conclusion

With a strong focus on innovation, a diverse product portfolio, and a commitment to improving patient outcomes, AngioDynamics is well-positioned in the medical technology space. By addressing critical health challenges through minimally invasive solutions, the company continues to play a vital role in advancing healthcare practices worldwide.

Rhea-AI Summary
AngioDynamics, Inc. (ANGO) has settled all outstanding patent litigation with Becton, Dickinson and Company (BD) through a settlement agreement, involving licensing agreements and a $7 million lump sum payment. The agreement includes annual payments to BD and potential additional payments based on net sales. The settlement resolves a multi-year patent dispute, providing clarity and allowing AngioDynamics to focus on innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
none
-
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) will report Q3 fiscal year 2024 financial results on April 4, 2024, followed by a conference call. Investors can access the call via phone or webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences earnings
-
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) announced participation in Oppenheimer conference for discussing healthcare and medtech innovations. The company aims to enhance blood flow, cancer treatments, and patient well-being.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) completes the sale of its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash. The company discontinues sales of radiofrequency ablation and Syntrax products to streamline its portfolio. The divestiture and discontinuation are part of the company's strategic focus on driving growth and profitability within its Med Tech platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary
AngioDynamics, Inc. (ANGO) has received FDA clearance for the Auryon XL Catheter, expanding access points in atherectomy procedures for the treatment of Peripheral Arterial Disease (PAD). The catheter's innovative design aims to reduce access site complications and accelerate patient recovery. The company anticipates a full market release in February 2024 after a limited market release in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced net sales of $79.1 million for the second quarter of fiscal year 2024, with a 2.7% increase on a pro-forma basis compared to the prior-year quarter. The company reported a GAAP loss per share of $0.72 and adjusted loss per share of $0.05. Cash and cash equivalents at November 30, 2023, were $60.9 million. The company expects to achieve full-year adjusted EPS profitability in FY27.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.87%
Tags
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) announced that its President and CEO, Jim Clemmer, and EVP and CFO, Stephen Trowbridge, will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 11, 2024. The presentation will focus on the company's medical technology innovations and cancer treatment advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) will report financial results for Q2 of fiscal year 2024 on January 5, 2024. The management will host a conference call to discuss the results, accessible via phone or webcast. The webcast replay and call recording will also be available for a limited time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences earnings
-
Rhea-AI Summary
AngioDynamics, Inc. (NASDAQ: ANGO) has completed the patient enrollment in the APEX-AV study, evaluating the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System for treating acute intermediate-risk pulmonary embolism (PE). The study enrolled 122 patients across 25 hospital-based sites in the US, with a focus on reducing thrombus burden and improving right ventricular function. The primary efficacy and safety endpoints of the study are the reduction in RV/LV ratio and the rate of Major Adverse Events (MAEs) within the first 48 hours post-procedure. The study aims to broaden the treatment options for PE, which affects around 900,000 people in the US every year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
none
Rhea-AI Summary
AngioDynamics, Inc. reports Q1 FY2024 financial results with net sales of $78.7 million, a 5.7% increase excluding Dialysis and BioSentry sales. Med Tech net sales increased 13.3% to $25.9 million. Gross margin declined 20 basis points to 50.9% on a pro-forma basis. Completed sale of Dialysis and BioSentry businesses for $100 million. Adjusted loss per share of $0.12. Cash and cash equivalents at $57.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags

FAQ

What is the current stock price of Angiodynamics (ANGO)?

The current stock price of Angiodynamics (ANGO) is $9.29 as of February 28, 2025.

What is the market cap of Angiodynamics (ANGO)?

The market cap of Angiodynamics (ANGO) is approximately 382.0M.

What does AngioDynamics specialize in?

AngioDynamics specializes in designing and manufacturing minimally invasive medical devices for oncology, vascular health, and dialysis treatments.

What is the NanoKnife® System?

The NanoKnife® System is a cutting-edge technology developed by AngioDynamics that uses irreversible electroporation to treat tumors with precision and minimal invasiveness.

Who are AngioDynamics' primary customers?

AngioDynamics primarily serves healthcare professionals, including interventional radiologists, nephrologists, and surgeons, who use its devices in therapeutic and diagnostic procedures.

How does AngioDynamics differentiate itself from competitors?

AngioDynamics sets itself apart through its focus on niche technologies like the NanoKnife® System and its commitment to minimally invasive solutions that improve patient outcomes.

What challenges does AngioDynamics face in its industry?

Challenges include navigating regulatory compliance, maintaining innovation in a competitive market, and addressing pricing pressures in the healthcare sector.

What is AngioDynamics' approach to innovation?

AngioDynamics prioritizes research and development to create next-generation medical devices that address evolving healthcare needs and improve clinical outcomes.

Where does AngioDynamics generate most of its revenue?

The majority of AngioDynamics' revenue comes from the U.S. market, though the company is expanding its presence internationally.

What role does AngioDynamics play in the healthcare industry?

AngioDynamics plays a crucial role by providing advanced medical devices that enable minimally invasive treatments, improving patient care and procedural efficiency.
Angiodynamics

Nasdaq:ANGO

ANGO Rankings

ANGO Stock Data

382.00M
38.19M
5.6%
81.3%
2.47%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
LATHAM